10-Q: Hi-Great Group Holding Company Reports First Quarter 2024 Results, Revenue Declines

Hi-Great Group Holding Company reported a net loss of $3,918 on $9,050 in sales for the quarter ended March 31, 2024, a decrease in revenue compared to the same period last year.

Summary

• Hi-Great Group Holding Company reported a net loss of $3,918 for the quarter ended March 31, 2024, compared to a net loss of $7,959 for the same period in 2023.
• Sales for the quarter were $9,050, a decrease from $24,269 in the first quarter of 2023.
• The cost of sales was $4,873 for the quarter, down from $11,397 in the prior year's first quarter.
• Professional fees decreased to $6,500 from $7,000 year-over-year.
• General and administrative expenses decreased to $1,596 from $6,490 year-over-year.
• The company had no interest expense in the current quarter, compared to $2,276 in the same quarter of the previous year.
• The company's accumulated deficit is $842,897 as of March 31, 2024.
• Cash received from operating activities was $954, compared to $19,188 in the same period last year.
• The company has 100,000,000 shares of common stock issued and outstanding as of May 29, 2024.

Sentiment

Score: 3

Explanation: The document shows a company with declining revenue, ongoing losses, and significant operational risks. While there are some improvements in loss reduction, the overall financial health and operational structure raise concerns.

Positives

• The net loss decreased by approximately 50% compared to the same quarter last year.
• Operating expenses, including professional fees and general and administrative expenses, decreased year-over-year.
• The company had no interest expense in the current quarter, compared to $2,276 in the same quarter of the previous year.
• The company's cash position increased slightly to $1,687 from $733 at the end of the previous quarter.

Negatives

• Sales decreased significantly to $9,050 from $24,269 year-over-year.
• The company continues to operate at a loss, with a net loss of $3,918 for the quarter.
• The company has an accumulated deficit of $842,897.
• Cash received from operating activities decreased significantly to $954 from $19,188 year-over-year.

Risks

• The company is a development stage enterprise and has not yet established an ongoing source of revenues sufficient to cover its operating costs.
• The company is dependent on debt and equity financing to fund its operations.
• There is no assurance that the company will be able to raise additional equity capital or be successful in the development and commercialization of its products.
• The company's disclosure controls and procedures were deemed not effective for the quarter ended March 31, 2024, due to a lack of an audit committee and segregation of duties.
• The company's future success is dependent on the general economy and its ability to successfully raise future financings.

Future Outlook

The company is focused on maximizing shareholder returns through dividends, sustainable growth in cash flows, potential appreciation in property values, and other agricultural business opportunities. They also plan to expand into the cosmetics sector and continue to market and distribute SellaCare, Inc.'s organic longevity health supplement.

Management Comments

• Management of the Company is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect.
• Management believes that it will be successful in its capital formation and planned operating activities.

Industry Context

The company is operating in the health supplement and potentially the cosmetics industry, which are both competitive markets. The company's focus on the KRAS gene and its licensing agreement with SellaCare, Inc. could provide a competitive advantage if successful. However, the company's current financial performance indicates it is still in a development stage and faces significant challenges.

Comparison to Industry Standards

• It is difficult to compare Hi-Great Group Holding Company to industry standards due to its development stage and unique business model.
• Many companies in the health supplement industry have established revenue streams and are not reliant on related party transactions to the same extent.
• The company's lack of an audit committee and segregation of duties is not in line with best practices for public companies.
• The company's reliance on a single licensing agreement with SellaCare, Inc. is a risk compared to companies with diversified product portfolios.

Management Changes

Corporate Governance

Related Party Transactions

• The company has a licensing agreement with SellaCare, Inc., which is controlled by the company's majority shareholder, requiring a 25% royalty payment on gross revenues.
• The company leases land from Sella Property, LLC, an entity controlled by the company's majority shareholder.
• The company had a loan from Jung Ho Yang and Sellacare America, Inc., both related parties, which have been paid.
• The company sells herbal supplements it buys directly from SellaCare, Inc.

Stakeholder Impact

• Shareholders are impacted by the company's ongoing losses and the need for additional capital.
• Employees are impacted by the company's financial instability and reliance on related party transactions.
• Customers are impacted by the company's ability to continue to provide products and services.
• Suppliers are impacted by the company's financial instability and ability to pay for goods and services.
• Creditors are impacted by the company's financial instability and ability to repay debts.

Next Steps

• The company will continue to focus on raising additional funding.
• The company will continue to develop and commercialize its products.
• The company will continue to market and distribute SellaCare, Inc.'s organic longevity health supplement.
• The company plans to expand into the cosmetics sector.

Key Dates

Keywords

financial results, quarterly report, net loss, revenue, operating expenses, development stage, related party transactions, going concern, KRAS gene, herbal supplements, cosmetics